Please login to the form below

Not currently logged in
Email:
Password:

BMS/Ono enter extended agreement

Bristol-Myers Squibb and Ono Pharmaceutical have announced an agreement to develop separate therapies for cancer and rheumatoid arthritis

Bristol-Myers Squibb (BMS) and Ono Pharmaceutical have announced an agreement to develop separate therapies for cancer and rheumatoid arthritis.

The agreement involving anti-PD-1 antibody known as BMS-936558/ONO-4538 consists of the expansion of BMS' territorial rights to develop and commercialise it. The drug is an investigational cancer immunotherapy which was created under a collaboration in May 2005 between Ono and Medarex.

When Medarex was acquired by BMS, it also gained the rights to develop and commercialise the anti-PD-1 antibody in North America. These rights have now been extended allowing BMS to develop and commercialise the drug around the world, except in Japan, Korea and Taiwan, where Ono has retained all rights.

The other agreement created is for the co-development and co-commercialisation of Orencia (abatacept) in Japan. The drug is a biologic therapy for the autoimmune disease rheumatoid arthritis, and is indicated for use in patients for whom other therapies have failed.

The agreement covers both the currently approved intravenous (IV) formulation and the subcutaneous (SC) formulation, as well as includes all current and future indications. Bristol-Myers K.K. (BMS's Japanese subsidiary) will distribute and book sales of Orencia IV. Ono will distribute and book the sales of Orencia SC.

21st September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics